文献速递核素与放射性配体治疗肿瘤 PET/CT

晚期转移性肉瘤患者中[177Lu]Lu-FAPI-2286的可行性与治疗潜力

Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-07-27

这项前瞻性研究纳入8例不可切除或常规治疗后复发的晚期转移性肉瘤患者,经[68Ga]Ga-FAPI-2286 PET/CT确认肿瘤摄取后接受[177Lu]Lu-FAPI-2286肽靶向放射性核素治疗。四周期治疗后未观察到3级或4级副作用,原发肿瘤平均体积缩小52.37%,转移灶SUVmax与TBR分别下降29.67%和43.66%。

要点

  • 8例晚期转移性肉瘤患者接受[177Lu]Lu-FAPI-2286治疗,剂量6660-7400 MBq,每周期间隔6-8周,共四周期。
  • 未观察到3级或4级副作用,所有参与者耐受良好。
  • 原发肿瘤平均体积缩小52.37%,转移灶SUVmax与TBR分别下降29.67%和43.66%。

核心结论

  • [177Lu]Lu-FAPI-2286肽靶向放射性核素治疗在肉瘤患者中耐受性良好、副作用轻微,放射性肽在肿瘤内滞留持久,并显示出有前景的治疗效果。
  • 该项前瞻性研究的初步结果需通过进一步临床试验确认。

研究设计与样本

  • 前瞻性研究,纳入8例不可切除或常规治疗后复发的晚期转移性肉瘤患者。
  • 治疗前经[68Ga]Ga-FAPI-2286 PET/CT确认肿瘤摄取。
  • 患者接受[177Lu]Lu-FAPI-2286肽靶向放射性核素治疗,共四周期,每周期剂量6660-7400 MBq,周期间隔6-8周。

主要发现

  • 四周期[177Lu]Lu-FAPI-2286治疗后未观察到3级或4级副作用,所有参与者耐受良好。
  • 原发肿瘤平均体积缩小52.37%。
  • 转移灶SUVmax下降29.67%,TBR下降43.66%,尤其在肺转移病例中。
  • 患者体力改善、疼痛减轻、总生存期延长,且治疗满意度提高。

关键数值与推荐

  • 每周期[177Lu]Lu-FAPI-2286剂量为6660-7400 MBq,周期间隔6-8周,共四周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该项前瞻性研究的初步结果需通过进一步临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The unique expression pattern of fibroblast activation protein (FAP) in stromal and tumor cells, particularly in sarcomas, and its absence in normal tissues, have positioned it as a promising theragnostic approach for the detection and treatment of various cancer types. The objective of this prospective study is to assess the feasibility, safety, biodistribution, and therapeutic efficacy of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. PATIENTS AND METHODS: Eight patients with advanced metastatic sarcoma, who were unresectable or had experienced disease recurrence following conventional treatments, underwent PTRT (peptide-targeted radionuclide therapy) using [177Lu]Lu-FAPI-2286. Prior to the treatment, confirmation of tumor uptake was obtained through [68Ga]Ga-FAPI-2286 PET/CT. RESULTS: After four cycles of PTRT with [177Lu]Lu-FAPI-2286 (6660-7400 MBq), with a 6-8-week interval between each cycle, no grade 3 or 4 side effects were observed in the patients, and the treatment was well tolerated by all participants. The results demonstrated a 52.37% reduction in the average volume of the primary tumor, accompanied by a significant decrease in SUVmax and TBR of the metastatic lesions (29.67% and 43.66% respectively), especially in cases of lung metastasis. Furthermore, besides the improvement in physical capacity, there was a noticeable reduction in pain, an increase in overall survival, and enhanced satisfaction with the treatment reported by the patients. CONCLUSION: [177Lu]Lu-FAPI-2286 PTRT, utilized for diverse cancer types, exhibited favorable tolerability in sarcoma patients, with minimal side effects, long-lasting retention of the radiopeptide within the tumor, and promising therapeutic effects. Preliminary findings of this prospective study need to be confirmed through further clinical trials.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Banihashemian SS, Akbari ME, Pirayesh E, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 39060377. doi:10.1007/s00259-024-06795-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。